Rocket Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Rocket Pharmaceuticals Inc.
- Former names
- Inotek Pharmaceuticals Corp
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- New York
- Headquarters state / province
- New York
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- RCKT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001281895
Board of directors
-
Carsten Boess · DirectorSince 2023
-
David P. Southwell · DirectorSince 2023
-
Elisabeth Bjork · DirectorSince 2023
-
Fady Ibraham Malik · DirectorSince 2023
-
Gaurav Shah · Director · CEOSince 2023
-
Gotham Makker · DirectorSince 2023
-
Keith Woods · DirectorSince 2023
-
Mikael Dolsten · DirectorSince 2024
-
Naveen Yalamanchi · DirectorSince 2023
-
Pedro P. Granadillo · DirectorSince 2023
-
Peter Fong · DirectorSince 2025
-
Piratip Pratumsuwan · DirectorSince 2025
-
Roderick Wong · DirectorSince 2023
Chief executives
Gaurav Shah
· CEO
Dates unknown
Director election results
Annual meeting of May 20, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
68.2%
-
94.0%
-
98.1%
-
99.1%
-
99.1%
-
99.2%
-
99.3%
Board connections
6 of this board's directors also sit on 8 other boards.
- via David P. Southwell and Keith Woods
- via Mikael Dolsten
- via Carsten Boess
- via Keith Woods
- via Roderick Wong
- via David P. Southwell
- via Elisabeth Bjork
- via Keith Woods
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $34,400
- 1 purchase by 1 insider
- Sold, last 12 months
- $978,814
- 29 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 11, 2026 | Wilson Martin Officer (General Counsel) | Open-market sale | −75,364 | $3.40 | $256,464 |
| Aug 18, 2026 | Gaurav Shah Officer (CEO) | Open-market sale | −2,293 | $3.38 | $7,753 |
| Aug 18, 2026 | Wilson Martin Officer (General Counsel) | Open-market sale | −631 | $3.38 | $2,133 |
| Aug 13, 2026 | Wilson Martin Officer (General Counsel) | Open-market sale | −3,493 | $3.38 | $11,810 |
| Aug 13, 2026 | Gaurav Shah Officer (CEO) | Open-market sale | −2,837 | $3.38 | $9,592 |
| Aug 11, 2026 | Chaudhuri Sarbani Officer (See Remarks) | Open-market sale | −4,701 | $3.50 | $16,449 |
| Aug 11, 2026 | Stevens Christopher James Officer (Chief Operating Officer) | Open-market sale | −36,658 | $3.50 | $128,266 |
| Aug 3, 2026 | David P. Southwell Director | Other | +150,000 | — | — |
| Aug 3, 2026 | Stevens Christopher James Officer (Chief Operating Officer) | Grant or award | +73,313 | — | — |
| Jun 18, 2026 | Carsten Boess Director | Grant or award | +22,862 | — | — |
| Jun 18, 2026 | Mikael Dolsten Director | Grant or award | +22,862 | — | — |
| Jun 18, 2026 | Peter Fong Director | Grant or award | +22,862 | — | — |
| Jun 18, 2026 | Fady Ibraham Malik Director | Grant or award | +22,862 | — | — |
| Jun 18, 2026 | David P. Southwell Director | Grant or award | +22,862 | — | — |
| Jun 18, 2026 | Roderick Wong Director, 10% owner | Grant or award | +27,832 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.